Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Total Valuation
Kura Oncology has a market cap or net worth of $496.07M. The enterprise value is ―.
Market Cap$496.07M
Enterprise Value―
Share Statistics
Kura Oncology has 86,574,684 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding86,574,684
Owned by Insiders1.40%
Owned by Institutions1.39%
Financial Efficiency
Kura Oncology’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -28.50%.
Return on Equity (ROE)-0.42
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.50%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee280.64K
Profits Per Employee-906.16K
Employee Count192
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kura Oncology is -4.31. Kura Oncology’s PEG ratio is 0.94.
PE Ratio-4.31
PS Ratio0.00
PB Ratio1.61
Price to Fair Value1.81
Price to FCF5.26
Price to Operating Cash Flow5.28
PEG Ratio0.94
Income Statement
In the last 12 months, Kura Oncology had revenue of 53.88M and earned -173.98M in profits. Earnings per share was -2.02.
Revenue53.88M
Gross Profit53.03M
Operating Income-193.19M
Pretax Income-171.97M
Net Income-173.98M
EBITDA-169.50M
Earnings Per Share (EPS)-2.02
Cash Flow
In the last 12 months, operating cash flow was 111.23M and capital expenditures -680.00K, giving a free cash flow of 110.55M billion.
Operating Cash Flow111.23M
Free Cash Flow110.55M
Free Cash Flow per Share1.28
Dividends & Yields
Kura Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change-73.16%
50-Day Moving Average6.54
200-Day Moving Average12.29
Relative Strength Index (RSI)45.38
Average Volume (3m)1.42M
Important Dates
Kura Oncology upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Kura Oncology as a current ratio of 9.46, with Debt / Equity ratio of 5.31%
Current Ratio9.46
Quick Ratio9.46
Debt to Market Cap0.02
Net Debt to EBITDA1.23
Interest Coverage Ratio-119.33
Taxes
In the past 12 months, Kura Oncology has paid 2.02M in taxes.
Income Tax2.02M
Effective Tax Rate-0.01
Enterprise Valuation
Kura Oncology EV to EBITDA ratio is -3.20, with an EV/FCF ratio of 4.05.
EV to Sales10.07
EV to EBITDA-3.20
EV to Free Cash Flow4.05
EV to Operating Cash Flow4.04
Balance Sheet
Kura Oncology has $658.19M in cash and marketable securities with $19.35M in debt, giving a net cash position of -$638.84M billion.
Cash & Marketable Securities$658.19M
Total Debt$19.35M
Net Cash-$638.84M
Net Cash Per Share-$7.38
Tangible Book Value Per Share$4.80
Margins
Gross margin is 99.40%, with operating margin of -358.55%, and net profit margin of -322.89%.
Gross Margin99.40%
Operating Margin-358.55%
Pretax Margin-319.15%
Net Profit Margin-322.89%
EBITDA Margin-314.57%
EBIT Margin-316.14%
Analyst Forecast
The average price target for Kura Oncology is $22.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.60
Price Target Upside279.83% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast3.95%